• SCX.ai (ASX: SCX) Strategic Partnership With Global AI Leader DDN to Power Australia’s Largest Sovereign AI Inferencing Cloud

    • August 24, 2026
    • Posted by: Jessica Turner
    • Category: Competitive research
    No Comments

    Alliance to scale sovereign AI capacity as demand for Australian-based AI infrastructure growsSYDNEY, Aug. 24, 2026 /PRNewswire/ — Australian sovereign AI infrastructure pioneer SCX.ai and global AI data intelligence leader DDN today announced a landmark partnership to expand and…

    read more

  • Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

    • August 24, 2026
    • Posted by: Victoria Reynolds
    • Category: Economics
    No Comments

    – ASP2138’s advancement into Phase 3 marks an important milestone in Astellas’ commitment to advancing research in CLDN18.2 with its differentiated portfolio, spanning approved treatments and investigational assets – TOKYO, Aug. 24, 2026 /PRNewswire/ — Astellas Pharma Inc. (TSE:…

    read more

  • Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion

    • August 24, 2026
    • Posted by: Victoria Reynolds
    • Category: Economics
    No Comments

    TAIPEI, Aug. 23, 2026 /PRNewswire/ — Anbogen Therapeutics Inc. (TPEx: 7784) (“Anbogen” or the “Company”), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate…

    read more